Which companies are affected by this news?

Companies directly affected include: RDHL, RPD, NB.

Which industries does this news affect?

AlphaOS tracks industry-level impact for all major market events.

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

Q: What is the market impact of: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation?

AlphaOS is tracking this market event: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation.

July 10, 2026 · Updated Jul 10, 2026

Affected Companies

RDHL43

RedHill Biopharma Ltd.

NIOCORP DEVELOPMENTS LTD

$4.69$682.80M cap

AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.